keyword
MENU ▼
Read by QxMD icon Read
search

Ulcerative colitis tnf

keyword
https://www.readbyqxmd.com/read/28922365/isothiocyanate-enriched-moringa-seed-extract-alleviates-ulcerative-colitis-symptoms-in-mice
#1
Youjin Kim, Alex G Wu, Asha Jaja-Chimedza, Brittany L Graf, Carrie Waterman, Michael P Verzi, Ilya Raskin
Moringa (Moringa oleifera Lam.) seed extract (MSE) has anti-inflammatory and antioxidant activities. We investigated the effects of MSE enriched in moringa isothiocyanate-1 (MIC-1), its putative bioactive, on ulcerative colitis (UC) and its anti-inflammatory/antioxidant mechanism likely mediated through Nrf2-signaling pathway. Dextran sulfate sodium (DSS)-induced acute (n = 8/group; 3% DSS for 5 d) and chronic (n = 6/group; cyclic rotations of 2.5% DSS/water for 30 d) UC was induced in mice that were assigned to 4 experimental groups: healthy control (water/vehicle), disease control (DSS/vehicle), MSE treatment (DSS/MSE), or 5-aminosalicyic acid (5-ASA) treatment (positive control; DSS/5-ASA)...
2017: PloS One
https://www.readbyqxmd.com/read/28922253/long-term-efficacy-safety-and-immunogenicity-of-biosimilar-infliximab-after-one-year-in-a-prospective-nationwide-cohort
#2
Lorant Gonczi, Krisztina B Gecse, Zsuzsanna Vegh, Zsuzsanna Kurti, Mariann Rutka, Klaudia Farkas, Petra A Golovics, Barbara D Lovasz, Janos Banai, Laszlo Bene, Bea Gasztonyi, Tunde Kristof, Laszlo Lakatos, Pal Miheller, Ferenc Nagy, Karoly Palatka, Maria Papp, Arpad Patai, Agnes Salamon, Tamas Szamosi, Zoltan Szepes, Gabor T Toth, Aron Vincze, Balazs Szalay, Tamas Molnar, Peter L Lakatos
BACKGROUND: It has been previously shown that biosimilar infliximab CT-P13 is effective and safe in inducing remission in inflammatory bowel diseases. We report here the 1-year outcomes from a prospective nationwide inflammatory bowel disease cohort. METHODS: A prospective, nationwide, multicenter, observational cohort was designed to examine the efficacy and safety of CT-P13 in the induction and maintenance treatment of Crohn's disease (CD) and ulcerative colitis (UC)...
August 23, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28905102/digestive-system-in-psoriasis-an-update
#3
REVIEW
Daniel Pietrzak, Aldona Pietrzak, Dorota Krasowska, Andrzej Borzęcki, Kinga Franciszkiewicz-Pietrzak, Beata Polkowska-Pruszyńska, Maja Baranowska, Kristian Reich
Psoriasis is a chronic inflammatory immune-mediated disorder associated and often coexisting with many other immune-related clinical conditions including those affecting the gastrointestinal tract. Data obtained from the reviewed literature suggest an association between psoriasis and pathologies of the oral cavity, both psoriasis-specific lesions, as well as non-specific, such as geographic tongue or fissured tongue. These findings show the importance of thorough examination of oral mucosa in psoriatic patients...
September 13, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/28891095/biological-and-clinical-implications-of-herbal-medicine-and-natural-products-for-the-treatment-of-inflammatory-bowel-disease
#4
REVIEW
Bao-Jian Guo, Zhao-Xiang Bian, Hong-Cong Qiu, Yi-Tao Wang, Ying Wang
Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders that includes Crohn's disease (CD) and ulcerative colitis (UC). Homeostasis of various regulatory factors involved with intestinal immunity is disrupted in IBD, including the intestinal epithelial barrier, macrophages, and cellular mediators such as cytokines and chemokines. No successful treatment is currently available for the management of IBD. Natural products and herbal medicines have exhibited efficacy for UC and CD in experimental models and clinical trials with the following activities: (1) maintenance of integrity of the intestinal epithelial barrier, (2) regulation of macrophage activation, (3) modulation of innate and adaptive immune response, and (4) inhibition of TNF-α activity...
August 2017: Annals of the New York Academy of Sciences
https://www.readbyqxmd.com/read/28890660/flow-cytometric-immune-profiling-in-infliximab-associated-tuberculosis
#5
Kelly Pennington, Humberto C Sasieta, Guiherme P Ramos, Courtney L Erskine, Virginia P Van Keulen, Tobias Peikert, Patricio Escalante
Tumor necrosis factor α antagonists are increasingly used to treat inflammatory and autoimmune disorders and are associated with increased risk of active tuberculosis. Diagnosis of active tuberculosis in patients taking tumor necrosis factor α antagonists can be challenging owing to increased incidence of extrapulmonary manifestations and false-negative results on current available diagnostic tests. We present a case of a young woman on infliximab for ulcerative colitis who presented with disseminated tuberculosis...
2017: Clinical Medicine Insights. Case Reports
https://www.readbyqxmd.com/read/28887965/preparation-characterization-and-anti-colitis-activity-of-curcumin-asafoetida-complex-encapsulated-in-turmeric-nanofiber
#6
Sreeraj Gopi, Augustine Amalraj, Shintu Jude, Karthik Varma, T R Sreeraj, Józef T Haponiuk, Sabu Thomas
Ulcerative colitis (UC) is a main form of inflammatory bowel disease (IBD). Asafoetida (ASF) and turmeric have traditionally been used for the treatment of various inflammatory diseases, including UC, because ASF is rich in sulfur compounds and turmeric contains curcumin (CUR). Turmeric nanofiber (TNF), the modified cell wall component of turmeric is considered to play important role in the human diet, health and can be used as a carrier agent to encapsulate bioactive components. A novel gut health product (GHP) was formulated by encapsulation of ASF and CUR complex onto TNF...
December 1, 2017: Materials Science & Engineering. C, Materials for Biological Applications
https://www.readbyqxmd.com/read/28884254/elderly-onset-and-adult-onset-ulcerative-colitis-are-more-similar-than-previously-reported-in-a-nationwide-cohort
#7
Vinayak Kumar, Yash Shah, Dhruvan Patel, Nabeel Khan
BACKGROUND: Elderly-onset ulcerative colitis (EO-UC) is recognized as a distinct subpopulation of UC. To our knowledge, there have been no nationwide studies of EO-UC populations in the USA. AIMS: We aim to characterize differences in presentation at diagnosis and clinical course between EO-UC and adult-onset UC (AO-UC) patients in a national cohort. METHODS: Complete medical records of patients newly diagnosed with UC from October 2001 to October 2011 in the Veterans Affairs health system were obtained...
September 7, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28879208/tumor-necrosis-factor-alpha-inhibitor-induced-acute-pancreatitis
#8
Monia E Werlang, Michele D Lewis, Michael J Bartel
Treatment of acute pancreatitis remains a challenge, with therapy focused on supportive care and treating the inciting etiology. Tumor necrosis factor-alpha (TNFα) inhibitors have shown promising results treating acute pancreatitis in animal models, but they have not been evaluated in human trials yet. A 25-year-old woman presented with ulcerative colitis. She was unresponsive to immunomodulators and developed acute pancreatitis shortly after initiation of a TNFα inhibitor. Her symptoms subsided after discontinuation of the medication, but reemerged when a different TNFα inhibitor was introduced to control her ulcerative colitis...
2017: ACG Case Reports Journal
https://www.readbyqxmd.com/read/28877085/current-health-status-and-medical-therapy-of-patients-with-pediatric-onset-inflammatory-bowel-disease-a-survey-based-analysis-on-1280-patients-aged-10-25-years-focusing-on-differences-by-age-of-onset
#9
Antje Timmer, Renee Stark, Jenny Peplies, Martin Classen, Martin W Laass, Sibylle Koletzko
OBJECTIVE: There are inconsistent reports on age-related differences in inflammatory bowel disease (IBD). On the basis of patient information, we describe the clinical presentation and therapy in relation to age at diagnosis in longstanding pediatric IBD. PATIENTS AND METHODS: Two surveys were conducted in children and young adults (age: 10-25 years) by pretested postal questionnaires. The main analyses are descriptive, showing proportions and distributions per grouped age of diagnosis...
September 4, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28857361/modulation-of-vipergic-phenotype-of-enteric-neurons-by-colonic-biopsy-supernatants-from-patients-with-inflammatory-bowel-diseases-involvement-of-il-6-in-crohn-s-disease
#10
F Soufflet, M Biraud, M Rolli-Derkinderen, B Lardeux, C Trang, E Coron, S Bruley des Varannes, A Bourreille, M Neunlist
BACKGROUND: Neuroplastic changes in the enteric nervous system (ENS) observed during IBD might participate in physiopathological processes. Vasoactive intestinal polypeptide has been shown to be involved in intestinal inflammation and barrier functions. We aimed to investigate the modulation of VIP expression in colonic biopsies of IBD patient, the ability of soluble factors from biopsies to reproduce in vitro these modulations and identify soluble factors responsible. METHODS: VIP and cytokines mRNA expressions were assessed in colonic biopsies of healthy subjects (HS) and IBD patients from inflamed (I) and non-inflamed areas (NI)...
August 31, 2017: Neurogastroenterology and Motility: the Official Journal of the European Gastrointestinal Motility Society
https://www.readbyqxmd.com/read/28854064/microrna-141-is-involved-in-ulcerative-colitis-pathogenesis-via-aiming-at-cxcl5
#11
Mao Cai, Suping Chen, Wanle Hu
MicroRNAs (miRNAs) are gene expression's important posttranscriptional regulators. The precise function of miRNAs in ulcerative colitis (UC) is not entirely known. Our investigation's aim was to identify miRNAs induced in patients with active UC and to evaluate miR-141 influences on ameliorating intestinal inflammation. The miRNA expression profiles in patients suffering active UC (n = 15) and healthy individuals used as control (n = 13) were assessed adopting miRNA microarrays. Via quantitative real-time polymerase chain reaction, miR-141 expression was confirmed...
September 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/28842689/altered-expression-of-tumor-necrosis-factor-alpha-induced-protein-3-correlates-with-disease-severity-in-ulcerative-colitis
#12
Ishani Majumdar, Vineet Ahuja, Jaishree Paul
Ulcerative colitis (UC), an inflammatory disorder of the colon arises from dysregulated immune response towards gut microbes. Transcription factor NFκB is a major regulatory component influencing mucosal inflammation. We evaluated expression of Tumor Necrosis Factor Alpha Induced Protein3 (TNFAIP3), the inhibitor of NFκB activation and its associated partners ITCH, RNF11 and Tax1BP1 in inflamed mucosa of UC patients. We found highly significant up-regulated mRNA expression of TNFAIP3 that negatively correlated with disease activity in UC...
August 25, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28839870/use-of-anti-tnf-drug-levels-to-optimise-patient-management
#13
REVIEW
Konstantinos Papamichael, Adam S Cheifetz
Anti-tumour necrosis factor (TNF) therapies, such as infliximab, adalimumab, certolizumab pegol and golimumab, have been proven to be effective for the treatment of patients with Crohn's disease and ulcerative colitis. However, 10%-30% of patients with inflammatory bowel disease (IBD) show no initial clinical benefit to anti-TNF therapy (primary non-response), and over 50% after an initial favourable outcome will lose response over time (secondary loss of response (SLR)). Numerous recent studies in IBD have revealed an exposure-response relationship suggesting a positive correlation between high serum anti-TNF concentrations and favourable therapeutic outcomes including clinical, biomarker and endoscopic remission, whereas antidrug antibodies have been associated with SLR and infusion reactions...
October 2016: Frontline Gastroenterology
https://www.readbyqxmd.com/read/28838334/effects-of-curcumin-plus-soy-oligosaccharides-on-intestinal-flora-of-rats-with-ulcerative-colitis
#14
G Huang, L Ye, G Du, Y Huang, Y Wu, S Ge, Z Yang, G Zhu
To explore the therapeutic effect of curcumin (Cur) and soybean oligosaccharides (SBOS) on ulcerative colitis (UC) through testing the intestinal flora and ulcerative colitis (UC). 80 male SD rats were selected divided into four groups with 20 rats in each group: normal group, sulfasalazine (SASP) group, model group and group of curcumin plus soy oligosaccharide. All animals were treated for 4 weeks. In the fifth week rats were decapitated. Macroscopic damage scores of colonic mucosa were calculated. A 4mL blood sample was taken to detect the contents of serum tumor necrosis factor -α (TNF-α) and interleukin 8 (IL-8) by the double antibody sandwich ABC-ELISA method (enzyme-linked immunosorbent assay)...
August 15, 2017: Cellular and Molecular Biology
https://www.readbyqxmd.com/read/28837522/risk-factors-and-clinical-outcomes-in-patients-with-ibd-with-melanoma
#15
Loes H C Nissen, Marieke Pierik, Lauranne A A P Derikx, Elke de Jong, Wietske Kievit, Tim R A van den Heuvel, Alexander R van Rosendael, Elsemieke I Plasmeijer, Pieter Dewint, Rob H A Verhoeven, Lucy I H Overbeek, Iris D Nagtegaal, Frank Hoentjen, Andrea E van der Meulen-de Jong
BACKGROUND: Patients with inflammatory bowel disease (IBD) are at increased risk to develop malignant melanoma and this risk may increase with use of anti-tumor necrosis factor (TNF) therapy. Impaired survival of immunosuppressed melanoma patients is reported in transplant and rheumatology patients. This study aims to (1) identify risk factors for melanoma development in patients with IBD, (2) compare clinical characteristics of melanoma in patients with IBD to the general population, and (3) assess the influence of immunosuppressive medication on survival...
August 22, 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28837372/update-upon-efficacy-and-safety-of-etanercept-for-the-treatment-of-spondyloarthritis-and-juvenile-idiopathic-arthritis
#16
Giuseppe Murdaca, Simone Negrini, Ottavia Magnani, Elena Penza, Marco Pellecchio, Rossella Gulli, Paola Mandich, Francesco Puppo
TNF-α inhibitors have demonstrated efficacy both as monotherapy and in combination with disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of chronic inflammatory immune-mediated diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis (AS), psoriasis (Ps) and/or psoriatic arthritis (PsA) and may be administered off-label to treat disseminated granuloma annulare, systemic lupus erythematosus and systemic sclerosis. There are several TNF-α inhibitors available for clinical use including infliximab, adalimumab, golimumab, certolizumab pegol and etanercept...
August 24, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28829369/systemic-chemokine-levels-with-gut-specific-vedolizumab-in-patients-with-inflammatory-bowel-disease-a-pilot-study
#17
Stephanie Zwicker, Ronaldo Lira-Junior, Charlotte Höög, Sven Almer, Elisabeth A Boström
Vedolizumab, a gut-specific biological treatment for inflammatory bowel disease (IBD), is an antibody that binds to the α₄β₇ integrin and blocks T-cell migration into intestinal mucosa. We aimed to investigate chemokine levels in serum of IBD-patients treated with vedolizumab. In this pilot study, we included 11 IBD patients (8 Crohn's disease, 3 ulcerative colitis) previously non-respondent to anti-tumor necrosis factor (TNF)-agents. Patients received vedolizumab at week 0, 2 and 6 and were evaluated for clinical efficacy at week 10...
August 22, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28826742/a-comprehensive-review-and-update-on-crohn-s-disease
#18
Mahesh Gajendran, Priyadarshini Loganathan, Anthony P Catinella, Jana G Hashash
The term inflammatory bowel disease (IBD) refers principally to two major categories of chronic relapsing inflammatory intestinal disorders: Crohn's disease (CD) and ulcerative colitis (UC). In the United States, it is currently estimated that about 1.5 million people suffer from IBD, causing considerable suffering, mortality and economic loss every year. Yet the cause of IBD is unknown, and until we understand more, prevention or cure will not be possible. There is a lot of variation in the incidence and prevalence of CD based on geographic region, environment, immigrant population, and ethnic groups...
August 18, 2017: Disease-a-month: DM
https://www.readbyqxmd.com/read/28826571/indicators-of-suboptimal-tumor-necrosis-factor-antagonist-therapy-in-inflammatory-bowel-disease
#19
James O Lindsay, Alessandro Armuzzi, Javier P Gisbert, Bernd Bokemeyer, Laurent Peyrin-Biroulet, Geoffrey C Nguyen, Michael Smyth, Haridarshan Patel
BACKGROUND: Inflammatory bowel disease (IBD) is refractory to treatment in one-half of patients. AIMS: To evaluate the occurrence of suboptimal therapy among patients with IBD treated with tumor necrosis factor antagonists (anti-TNFs). METHODS: A multinational chart review in Europe and Canada was conducted among IBD patients diagnosed with ulcerative colitis (UC) or Crohn's disease (CD) who initiated anti-TNF therapy between 2009 and 2013...
August 1, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/28822915/immunomodulatory-effects-of-m2000-%C3%AE-d-mannuronic-acid-on-tnf-%C3%AE-il-17-and-foxp3-gene-expression-in-patients-with-inflammatory-bowel-disease
#20
Hussaini Alhassan Mohammed, Ali Akbar Saboor-Yaraghi, Homayoun Vahedi, Mir Saeed Yekaninejad, Ghodratollah Panahi, Gholamreza Hemmasi, Mostafa Lakzaei, Abbas Mirshafiey
INTRODUCTION: Inflammatory bowel diseases (IBD) are immune-mediated disorders that result from an aberrant immunological response to the gut luminal antigen in genetically susceptible patients. IBD is categorized into two serotype, Crohn's diseases (CD) and ulcerative colitis (UC), both subtype are important cause of gastrointestinal diseases. The increasing rate of hospitalization, with the high economic burden experienced by the IBD patients, calls for more concerted research efforts to design a potent and affordable treatment option for the treatment of IBD...
August 17, 2017: International Immunopharmacology
keyword
keyword
22393
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"